GlassScriptPhysician profile
Kristopher S Lybarger
NPI 1013172022
$742,956.73
in general payments reported to CMS, 2019-2025
40 companies · $80K in 2025
The $80K reported for 2025 was more than what 98% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132K · 2020: $13K · 2021: $26K · 2022: $96K · 2023: $209K · 2024: $188K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $137K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $134K · Travel and Lodging: $102K · Consulting Fee: $91K · Food and Beverage: $11K · Education: $204 · Gift: $34.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $136,975.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $133,883.50 |
| Travel and Lodging | $102,375.28 |
| Consulting Fee | $91,423.09 |
| Food and Beverage | $11,294.48 |
| Education | $203.55 |
| Gift | $34.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $342,921.46 | 2020-2025 | Arista Ah Flexitip, Arista, Phasix Mesh |
| Glaxosmithkline, LLC. | $176,977.31 | 2020-2025 | Jemperli, Zejula |
| Tesaro, INC. | $94,522.20 | 2019 | |
| Clovis Oncology, INC. | $40,964.79 | 2019-2022 | |
| Seagen INC. | $24,462.27 | 2021-2023 | Tivdak |
| Genmab U.S., INC. | $21,694.87 | 2022-2025 | Tivdak |
| Myriad Genetic Laboratories, INC. | $9,226.63 | 2019-2024 | Myrisk |
| Medical Device Business Services, INC. | $8,254.30 | 2021-2022 | |
| Immunogen, INC. | $6,551.74 | 2023 | Elahere |
| Intuitive Surgical, INC. | $6,453.95 | 2019-2023 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $2,711.35 | 2019-2025 | Lynparza, Calquence, Enhertu |
| Becton, Dickinson and Company | $1,184.63 | 2022-2024 | Arista Ah Flexitip |
| Merck Sharp & Dohme LLC | $1,126.91 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Ethicon US, LLC | $1,112.73 | 2019-2024 | Surgicel Nu-Knit, Ethicon |
| Karyopharm Therapeutics INC. | $1,043.13 | 2023 | Xpovio |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon INC. | $1,010.00 | 2021 | |
| Pfizer INC. | $917.85 | 2024 | |
| Abbvie INC. | $595.32 | 2019-2025 | |
| Dysis Medical, INC. | $267.73 | 2022 | |
| Eisai INC. | $263.70 | 2022-2025 | |
| Janssen Biotech, INC. | $150.41 | 2023 | Erleada, Imbruvica, Darzalex |
| Genentech, INC. | $147.13 | 2023 | |
| Integra Lifesciences Corporation | $52.33 | 2019-2022 | |
| Olympus America INC. | $37.56 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.28 | 2022-2023 | Alunbrig |
| Verastem, INC. | $33.05 | 2025 | Avmapki Fakzynja Co-Pack |
| Kyowa Kirin, INC. | $30.59 | 2019 | |
| Teleflex LLC | $22.59 | 2025 | Quikclot |
| Gilead Sciences, INC. | $22.10 | 2024 | |
| Incyte Corporation | $21.66 | 2022 | |
| Daiichi Sankyo INC. | $21.27 | 2023 | Enhertu |
| Taiho Oncology, INC. | $19.90 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $19.84 | 2024 | Onivyde |
| Novartis Pharmaceuticals Corporation | $18.00 | 2022 | |
| Genzyme Corporation | $17.52 | 2024 | |
| G1 Therapeutics, INC. | $17.02 | 2023 | Cosela |
| Axonics, INC. | $14.39 | 2023 | Axonics |
| Therapeuticsmd, INC. | $11.22 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristopher Lybarger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.